Loading patent…
AssigneeInstitut Gustave Roussy
InventorsFATHIA MAMI-CHOUAIB, MARINE LECLERC, GEORGES BISMUTH
Estimating the term…
The present invention relates to the combined use of a neuropilin-1 (Nrp-1) neutralizing agent and of a programmed cell death-1 (PD-1) neutralizing agent for killing cancer cells, typically for treating cancer, as well as to corresponding pharmaceutical compositions and kits, and to corresponding diagnostic and therapeutic methods. The invention further relates to in vitro, ex vivo and in vivo methods for detecting CD8+ TILs capable of recognizing cancer cells, for predicting the response of a subject to anti-PD-1 treatment of cancer, and for identifying a subject who responds therapeutically to a treatment of cancer with an antibody combination therapy comprising anti-Nrp-1 and anti-PD-1 antibodies.
1-18. (canceled)
An in vitro or ex vivo method for detecting CD8+ TILs capable of recognizing cancer cells, the method comprising a) providing a biological sample comprising TILs and b) determining whether said TILs express Nrp-1, the expression of Nrp-1 by the TILs indicating that said TILs are capable of recognizing cancer cells.
A method for activating PD-1+ CD8+ tumor-infiltrating T lymphocytes (TILs) anti-cancer cell effector functions and/or for enhancing cancerous tumor infiltration by PD-1+ CD8+ TILs having active anti-cancer cells effector functions, or for treating cancer, in a subject, wherein the method comprises a step of administering, to a subject having a cancer Nrp-1+ CD8+ tumor-infiltrating T lymphocytes (TILs) exhibiting anti-cancer cell effector functions and/or enhanced cancerous tumor infiltration ability, wherein said TILs have been obtained from the subject having a cancer and have been amplified ex vivo before the administration step.
A method for treating cancer in a subject, wherein the method comprises a step of administering an antibody combination comprising an effective amount of i) a Nrp-1 neutralizing antibody and ii) an immunotherapeutic antibody to a subject having a cancer, said subject expressing Nrp-1+ CD8+ TILs or Nrp-1+ PD-1+ CD8+ TILs.
Dependencies are inferred from the claim text.